Torii Pharmaceutical Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Torii Pharmaceutical Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Torii Pharmaceutical Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Torii Pharmaceutical Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Torii Pharmaceutical Co Ltd (Torii), a subsidiary of Shionogi & Co Ltd, is a pharmaceutical company. It develops and markets pharmaceutical products for chronic kidney disease (CKD), skin diseases, and allergies. The company’s product portfolio includes Enaroy tablets for renal anemia, Riona tablets as a phosphate binder for hyperphosphatemia and iron deficiency anemia, Remitch capsules for pruritus in dialysis patients and Remitch OD tablets for those with swallowing difficulties. Torii has introduced Corectim ointments, the first topical JAK inhibitors for atopic dermatitis, and Antebate in multiple forms for inflammation reduction. The company also markets Cedarcure and Miticure Sublingual tablets for Japanese cedar pollinosis and house dust mite allergies, respectively. Torii is headquartered in Chuo-ku, Tokyo, Japan.
Headquarters
Japan
Address
Torii Nihonbashi Building, 4-1, Nihonbashi-Honcho 3-chome, Chuo-ku, Tokyo, 103-8439
Website
www.torii.co.jp
Telephone
81 3 32316811
No of Employees
592
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$396.3M
Torii Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Product Areas: | Alutard |
| Renal/Dialysis | Antebate |
| Skin Disease | Cedarcure |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Ownership Changes | In September, the company was acquired by Shionogi & Co. Ltd. |
| 2025 | Plans/Strategy | In May, the company announced its plans to sell its 54.84% stake to Shionogi & Co., Ltd for JPY70.3 billion. |
| 2024 | Regulatory Approval | In June, the company received manufacturing and marketing approval for Vtama Cream 1% (tapinarof) for the treatment of Atopic Dermatitis and Plaque Psoriasis in Japan. |
Competitor Comparison
| Key Parameters | Torii Pharmaceutical Co Ltd | Daiichi Sankyo Co Ltd | Chugai Pharmaceutical Co Ltd | Sumitomo Pharma Co Ltd | Maruho Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chuo-ku | Chuo-Ku | Chuo-Ku | Osaka | Kita |
| State/Province | Tokyo | Tokyo | Tokyo | Osaka | Osaka |
| No. of Employees | 592 | 19,765 | 7,872 | 3,832 | 1,632 |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kazuhiro Hatanaka | Chairman | Executive Board | - | - |
| Katsunobu Fujiwara | Director; Pharmaceutical Sales Group | Executive Board | - | - |
| Shinya Kondo | President; Representative Director | Senior Management | - | - |
| Noriaki Nishino | Executive Officer | Senior Management | - | - |
| Shinichiro Arikawa | Senior Executive Officer | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer